The role of capecitabine in locally advanced rectal cancer treatment: An update

Drugs

Volumn 72, Issue 8, 2012, Pages 1057-1073

  Fernández Martos, Carlos ^a   Nogué, Miquel ^b   Cejas, Paloma ^c   Moreno García, Vctor ^c,d   MacHancoses, Ana Hernández ^e   Feliu, Jaime ^c  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Bevacizumab; Capecitabine; Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ALOPECIA; ANASTOMOSIS LEAKAGE; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING TENDENCY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CHEMORADIOTHERAPY; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INFECTION; INTESTINE PERFORATION; LETHARGY; LEUKOPENIA; LOCALLY ADVANCED RECTAL CANCER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PROCTITIS; PROTEIN EXPRESSION; RADIATION INDUCED EMESIS; RECTUM CANCER; REVIEW; SIGMOIDOSCOPY; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SKIN TOXICITY; THROMBOSIS; TISSUE PRESSURE; TREATMENT RESPONSE; VOMITING; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS;

EID: 84861427510     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11633870-000000000-00000     Document Type: Review

References (102)

1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40
2. Byfield JE, Calabro-Jones P, Klisak I, et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982; 8: 1923-33 (Pubitemid 13167377)
3. Smalley SR, Kimler BF, Evans RG. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 1991; 20: 207-11
4. Omalley SR, Kimler BF, Evans RG. 5-Fluorouracil proving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-7
5. Smalley SR, Benedetti J, Williamson S, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006; 24 (22): 3542-7 (Pubitemid 46630524)
6. Glynne-Jones R, Dunst J, Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol 2006; 17: 361-71 (Pubitemid 43329571)
7. Ben-Josef E. Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer. Am J Clin Oncol 2007; 30 (6): 649-55 (Pubitemid 350307192)
8. Liauw S, Minsky B. The use of capecitabine in the combined-modality therapy for rectal cancer. Clin Colorectal Cancer 2008; 7 (2): 99-104 (Pubitemid 351518770)
9. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5 fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55 (7): 1091-7 (Pubitemid 28167730)
10. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur JCan. 1998; 34: 1274-81 (Pubitemid 28342121)
11. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-7 (Pubitemid 30151522)
12. Kovach JS, Beart Jr RW. Cellular pharmacology of fluorinated pyrimidines in vivo in man. Invest New Drugs 1989; 7: 13-25 (Pubitemid 19135297)
13. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948-53 (Pubitemid 29493974)
14. Dunst J, Reese T, Sutter T, et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002; 20: 3983-91
15. Ngan SY, Michael M, Mackay J, et al. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced potentially resectable rectal cancer. Br J Cancer 2004; 91: 1019-24 (Pubitemid 39336237)
16. Zampino GM, Magni E, Leonardi MC, et al. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2009; 75 (2): 421-7
17. Dunst J, Debus J, Rudat V, et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol 2008; 184: 450-6
18. Kim DY, Jung KH, Kim TH, et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67: 378-84 (Pubitemid 46108315)
19. De Paoli A, Chiara S, Luppi G, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006; 17: 247-51
20. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine (xeloda) and concomitant boost radiotherapy n patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66: 762-71 (Pubitemid 44436703)
21. Kim JC, Kim TW, Kim JH, et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2005 Oct 1; 63 (2): 346-53 (Pubitemid 41317150)
22. Das P, Lin EH, Bathia S, et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion with locally advanced rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 2006; 66: 1378-83
23. Dupuis O, Vie B, Lledo G, et al. Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR phase II study. Oncology 2007; 73: 169-76 (Pubitemid 351630046)
24. Yerushalmi R, Idelevich E, Dror Y, et al. Preoperative chemoradiation in rectal cancer: retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. J Surg Oncol 2006; 93: 529-33 (Pubitemid 43806987)
25. ChanAK,Wong AO, JenkenDA. Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer: is it equivalent to 5-FU infusion plus leucovorin and radiotherapy? Int J Radiat Oncol Biol Phys 2010; 76: 1413-9
26. Saif MW, Hashmi S, Zelterman D, et al. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer: a retrospective review. Int J Colorectal Dis 2008; 32: 139-45 (Pubitemid 350302509)
27. Hofheinz, Wenz FK, Post S, et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo) adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): long-term results of a randomized, phase III trial [abstract no. 3504]. J Clin Oncol 2011; 29 Suppl
28. Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABPR-04 [abstract no. 3503]. J Clin Oncol 2011; 29 Suppl
29. Seymour MT, Thompson LC, Wasan HS, et al., FOCUS2 Investigators; National Cancer Research Institute ColorectalCancer Clinical StudiesGroup.Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011; 377: 1749-59
30. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47 (Pubitemid 30644117)
31. André T, Boni C, Mouneddji-Boudiaf L, et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51 (Pubitemid 38702845)
32. Glynne-Jones R, Sebag-Montefiore S, Maughan TS, et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006; 17: 50-6 (Pubitemid 43033839)
33. Rödel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-104 (Pubitemid 46613485)
34. Machiels JPP, Duck L, Honhon B, et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005; 16: 1898-905 (Pubitemid 41724278)
35. Aristu JJ, Arbea L, Rodronhon B, et al. Phase I-II of concurrent capecitabine and oxaliplatin with preoperative intensity modulated radiotherapy in patients with locally advanced rectal cancer. Int J Radiation Oncology Biol Phys 2008; 71: 748-55
36. Ferná ndez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonante imaging-defined locally advanced rectal cancer: Grupo Cá ncer de Recto 3 Study. J Clin Oncol 2010; 28: 859-65
37. Carlomagno C, Farella A, Buci L, et al. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 2009; 20: 906-12
38. Sebag-Montefiore DJ, Rutten H, Rullier E, et al. Threeyear survival results of CORE (Capecitabine, Oxaliplatin, Radiotherapy, and Excision) study after postoperative chemotherapy in patients with locally advanced rectal adenocarcinoma [abstract no. 447]. Gastrointestinal Cancers Symposium; 2009 Jan 15-17; San Francisco (CA)
39. Fakih MG, BullardDunn K, Yang GY, et al. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Int J Radiation Oncology Biol Phys 2008; 72: 650-7
40. Koeberle D, Burkhard R, Moos R, et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 2008; 98: 1204-9 (Pubitemid 351481682)
41. Rödel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007; 25: 110-7 (Pubitemid 350003058)
42. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-44
43. Gérard JP, Gourgou-Bourgade S, Azria D, et al. Accord12/0405-prodige 2 phase III trial neoadjuvant treatment in rectal cancer: results after 3 years of follow-up. 2011 ASTRO Meeting. Int J Radiat Oncol Biol Phys 2011 Oct 1; 81 (2 Suppl.): S2
44. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J ClinOncol 2011; 29: 2773-80
45. Roedel C, Becker H, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial [abstract no. LBA3505]. J Clin Oncol 2011; 29 Suppl
46. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25: 3456-61 (Pubitemid 47310883)
47. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117-25
48. Ugidos L, Delgado S, Conill C, et al. Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients. Invest New Drugs 2009; 27: 262-8
49. Gollins SW, Myint S, Susnerwala S, et al. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2). Br J Cancer 2009; 101: 924-34
50. Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al. A phase II study of capecitabine and iriotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 2007; 96: 912-7 (Pubitemid 46452282)
51. Klautke G, Küchenmeister U, Foitzik T, et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006; 94: 976-81
52. Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005; 23: 1350-7
53. Cancer ResearchUKand UCL Cancer Trials Centre (UK). ARISTOTLE: Advanced Rectal study wIth Standard Therapy Or a novel agent, Total mesorectal excision (TME) and Long term Evaluation [ISRCTN Register no. ISRCTN09351447]. ISRCTN register [online]. Available from URL: http://www.controlled-trials.com [Accessed 2011 Jan 7]
54. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 2010 Sep; 21 (9): 1743-50
55. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-23 (Pubitemid 44394918)
56. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-5 (Pubitemid 46630960)
57. Chua YJ, Barbachana Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision inMRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 241-8
58. Schrag D, Weiser MR, Goodman K, et al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer [abstract no. 3511]. J Clin Oncol 2010; 28 (15 Suppl.)
59. Fernandez-Martos C, Safont MJ, Feliu J. Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): a GEMCAD study [abstract no. TPS196]. J Clin Oncol 2010; 28 (15 Suppl.)
60. Bonner JA, Harare PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8
61. Gaedcke J, Grade M, Jung K, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94 (1): 76-81
62. Machiels JP, Sempoux C, Scalliet P, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007; 18: 738-44 (Pubitemid 46523279)
63. Eisterer WM, De Vries A, Oefner D, et al. Neoadjuvant chemoradiation therapy with capecitabine plus cetuximab, and external beam radiotherapy in locally advanced rectal cancer: ABCSG trial R03 [abstract no. 4109]. J Clin Oncol 2009; 27 (15 Suppl.)
64. Velenik V, Ocvirk J, Oblak I, et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol 2010; 36 (3): 244-50
65. Chung KY, Minsky B, Schrag D, et al. Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer [abstract no. 3560]. J Clin Oncol 2006; 24 (18 Suppl.)
66. Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-fu, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2009; 73: 466-72
67. Hofheinz RD, Horisberger K, Woernle C, et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66: 1384-90
68. Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009; 74: 1487-93
69. Hong YS, Kim DY, Lee KS, et al. Phase II study of preoperative chemoradiation (CRT) with cetuximab, irinotecan and capecitabine in patients with locally advanced resectable rectal cancer [abstract no. 4045]. J Clin Oncol 2007; 25 (18 Suppl.)
70. Cabebe EC, Kuo T, Koong A, et al. Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer [abstract no. 15019]. J Clin Oncol 2008; 26 Suppl
71. Rödel C, Arnold D, Hipp M, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008; 70: 1081-6 (Pubitemid 351296110)
72. DewdneyA, CunninghamD, Tabernero J, et al. EXPERT-C: a randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/ oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer [abstract no. 360]. J Clin Oncol 2011; 29 Suppl. 4
73. Weiss C, Arnold D, Dellas K, et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys. Epub 2010 Feb 1-7
74. Bengala C, Bettelli S, Bertolini F, et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 2009; 20: 469-74
75. Debucquoy A, Haustermans K, Daemen A, et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009; 27: 2751-7
76. Nieder C, Wiedenmann N, Andratschke N, et al. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006; 32: 348-64 (Pubitemid 44063875)
77. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat Med 2004; 10 (2): 145-7 (Pubitemid 38524883)
78. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27(18): 3020-6
79. Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76 (3): 824-30
80. Czito B, Bendell JC, Willet CG, et al. Bevacizumab, oxaliplatin and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007; 68 (2): 472-8 (Pubitemid 46694189)
81. Landry JC, Catalano P, Cohen SJ, et al. Phase II study of preoperative radiation with concurrent capecitabine, oxaliplatin and bevacizumab followed by surgery and postoperative 5-FU, leucovorin, oxaliplatin (FOLFOX) and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Int J Radiat Oncol Biol Phys 2009; 75 (3 Suppl. 1): 27-8S
82. Kennecke H, Wong R, Berry S, et al. Bevacizumabcapecitabine, oxaliplatin radiation-rectal cancer trial (A-CORRECT) for locally advanced and lowrectal cancers. EJC Supplements. Vol 7; Issue 2. Sept 2009. P 332 Proc ECCO-ESMO 2009; 6037
83. Avallone A, Delrio P, Di Gennaro E, et al. Circulating endothelial cells and FDG-PET for early prediction of response in high-risk locally advanced rectal cancer patients treated with two different schedules of bevacizumab in combination with preoperative chemo-radiotherapy [abstract no. 6117]. EJC Supplements 2009 Sep; 7 (2): 358
84. Dipetrillo T, Pricolo V, Lagares-Garcia J, et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cá ncer. Int J Radiat Oncol Biol Phys 2012 Jan 1; 82 (1): 124-9
85. Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to induction plus concomitant XELOX chemoradiotherapy in MRI-poor prognosis locally-advanced rectal cancer: AVACROSS study [abstract no. 4100]. J Clin Oncol 2009; 27 Suppl. 15
86. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005 Dec 1; 23 (34): 8688-96 (Pubitemid 46211512)
87. Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007 May 1; 109 (9): 1750-5 (Pubitemid 46668536)
88. Moreno GV, Cejas P, Blanco CM, et al. Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis 2009 Jul; 24 (7): 741-8
89. Kawakami K, Salonga D, Park JM, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001 Dec; 7 (12): 4096-101 (Pubitemid 34044633)
90. Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001 Mar 15; 19 (6): 1779-86 (Pubitemid 32230880)
91. Liang K, Ang KK, Milas L, et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003 Sep 1; 57 (1): 246-54 (Pubitemid 36959763)
92. Meropol NJ, Gold PJ, Diasio RB, et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006 Sep 1; 24 (25): 4069-77 (Pubitemid 46622281)
93. Boskos CS, Liacos C, Korkolis D, et al. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. J Surg Oncol 2010 Oct 1; 102 (5): 408-12
94. Saw RP, Morgan M, Koorey D, et al. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 2003 Feb; 46 (2): 192-202 (Pubitemid 36222619)
95. Jakob C, Liersch T, Meyer W, et al. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol 2008 Feb 21; 14 (7): 1060-6 (Pubitemid 351325006)
96. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009 Jul 1; 74 (3): 673-88
97. Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005 Mar 20; 23 (9): 1826-38 (Pubitemid 46217459)
98. Kim IJ, Lim SB, Kang HC, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 2007 Sep; 50 (9): 1342-53 (Pubitemid 47472394)
99. Rimkus C, Friederichs J, Boulesteix AL, et al. Microarraybased prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 2008 Jan; 6 (1): 53-61 (Pubitemid 350309530)
100. Casado E, García VM, Sá nchez JJ, et al. A combined strategy of SAGE and quantitative PCR provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer. Clinical Cancer Research 2011; 17 (12): 4145-54
101. Allegra CJ, Yothers G, Osidy J, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results ofNSABP protocol C-08. J Clin Oncol 2010; 29: 11-16
102. R. M. Goldberg R, Sargent D, Thibodeau S, et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup phase III trial N0147 [abstract no. 3508]. J Clin Oncol 2010; 28: (15 Suppl.)